Phleomycin
(Synonyms: 腐草霉素,Zeocin) 目录号 : GC14081
Antibiotic used to select genetically-engineered cells
Cas No.:11006-33-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
Phleomycin is a glycopeptide antibiotic.
Glycopeptide antibiotics, a class of agents of microbial origin, are composed of glycosylated cyclic or polycyclic nonribosomal peptides. Significant glycopeptide antibiotics include the anti-infective and antitumor antibiotics.
In vitro: Previous study found that the chromosomes could be cleaved into nucleosomes and degraded by phleomycin over significantly narrower dose ranges than by bleomycin. In addition, phleomycin also showed lower specificity for internucleosomal cleavage than bleomycin. Moreover, it was found that the higher reactivity of phleomycin did not solely result from its higher rate of internucleosomal and intranucleosomal chromatin cleavage, since short phleomycin reactions always led to more extensive chromatin cleavage at low concentrations [1].
In vivo: A study of the in-vivo effects of phleomycin on meiosis of the mouse egg demonstrated a spectrum of damage to both first metaphase and second metaphase with polar body. The minimal effective dose in vivo of 2.5 μg/g of body weight could alter 28.3% of first metaphase figures and 50% of second metaphase cells [2].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Moore, C. W. Internucleosomal cleavage and chromosomal degradation by bleomycin and phleomycin in yeast. Cancer Research 48(23), 6837-6843 (1988).
[2] Jagiello GM. Action of phleomycin on the meiosis of the mouse ovum. Mutat Res. 1968 Sep-Oct;6(2):289-95.
| Cas No. | 11006-33-0 | SDF | |
| 别名 | 腐草霉素,Zeocin | ||
| 化学名 | (2R,3S,4S,5R,6R)-2-(((2R,3S,4S,5S,6S)-2-(2-(6-amino-2-(3-amino-1-((2,3-diamino-3-oxopropyl)amino)-3-oxopropyl)-5-methylpyrimidine-4-carboxamido)-3-((5-((1-((2-(4-((4-guanidinobutyl)carbamoyl)-4',5'-dihydro-[2,4'-bithiazol]-2'-yl)ethyl)amino)-3-hydroxy-1-o | ||
| Canonical SMILES | NC(CNC(CC(N)=O)C1=NC(N)=C(C(C(NC(C(NC(C(C(C)C(NC(C(NCCC2=NC(C3=NC(C(NCCCCNC(N)=N)=O)=CS3)CS2)=O)C(O)C)=O)O)C)=O)C(O[C@H]4[C@]([H])([C@H]([C@@H]([C@@H](O4)CO)O)O)O[C@H]5O[C@@H]([C@H]([C@@H]([C@@H]5O)OC(N)=O)O)CO)C6=CNC=N6)=O)=N1)C)C(N)=O.[Cu+2].Cl | ||
| 分子式 | C55H85N20O21S2Cu • HCl | 分子量 | 1526.5 |
| 溶解度 | ≤10mg/ml in PBS, pH 7.2 | 储存条件 | Store at 2-8°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.6551 mL | 3.2755 mL | 6.5509 mL |
| 5 mM | 0.131 mL | 0.6551 mL | 1.3102 mL |
| 10 mM | 0.0655 mL | 0.3275 mL | 0.6551 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。